The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > TRENDS
TRENDS
-
Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally
June 28, 2017
-
Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
April 10, 2017
-
Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
-
As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
-
Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
-
Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
February 7, 2017
-
AGs Set to Break into 10 Billion Yen Territory in Japan
November 14, 2016
-
Gilead Stays Pat on Hep C Plan, Japan Chief Says Innovation Outstrips Re-Pricing Hit
October 18, 2016
-
Japan’s Established Drug Market Shines as Renewed Opportunity for Foreign Generic Firms
September 26, 2016
-
Sumitomo Dainippon Feeling Sense of Crisis about Operating Profit to Approach Zero; Will Offer Early Retirement and Cut Executive Compensation
September 15, 2016
-
Surprise Rule Change Pops Up Yet Again, This Time with Taltz
September 5, 2016
-
Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
June 21, 2016
-
Success of Daiichi Sankyo’s New Midterm Plan to Hinge on Edoxaban; 120 Billion Yen Sales Target Set for FY2020
April 13, 2016
-
Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
February 17, 2016
-
Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
-
17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
-
Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
-
Takeda’s Exit from Diabetes Research a Symbolic Move under Weber Leadership
January 20, 2016
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…